Title:
PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES
Document Type and Number:
WIPO Patent Application WO/2019/079726
Kind Code:
A3
Abstract:
The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a phosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug, and one or more organoleptic, thixotropic, or both organoleptic and thixotropic agents.
Inventors:
HELSON LAWRENCE (US)
SHOPP GEORGE (US)
BOUCHARD ANNIE (CA)
MAJEED MUHAMMED (US)
SHOPP GEORGE (US)
BOUCHARD ANNIE (CA)
MAJEED MUHAMMED (US)
Application Number:
PCT/US2018/056721
Publication Date:
June 06, 2019
Filing Date:
October 19, 2018
Export Citation:
Assignee:
SIGNPATH PHARMA INC (US)
International Classes:
A61K9/127; A61K31/12; A61K31/445; A61K31/4545
Domestic Patent References:
| WO2012167212A2 | 2012-12-06 |
Foreign References:
| US20150343063A1 | 2015-12-03 | |||
| US20140065061A1 | 2014-03-06 | |||
| US20050233970A1 | 2005-10-20 |
Other References:
SHOPP, G. M. ET AL.: "Liposomes ameliorate Crizotinib- and Nilotinib- induced inhibition of the cardiac IKr channel and QTc prolongation", ANTICANCER RESEARCH, vol. 34, 2014, pages 4733 - 4740, XP055480638
Attorney, Agent or Firm:
FLORES, Edwin S. et al. (US)
Download PDF:
Previous Patent: MESOFLUIDIC DEVICE FOR CULTURE OF CELL AGGREGATES
Next Patent: POLYMERIC CELL CULTURING SURFACE HAVING HIGH CELL ADHESION
Next Patent: POLYMERIC CELL CULTURING SURFACE HAVING HIGH CELL ADHESION